Aurinia Pharmaceuticals - AUP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$16.76
▼ -0.61 (-3.51%)

This chart shows the closing price for AUP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aurinia Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUP

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$16.76.

This chart shows the closing price for AUP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Aurinia Pharmaceuticals. This rating has held steady since July 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/6/2021Royal Bank of CanadaReiterated RatingOutperformC$23.00
6/28/2021Royal Bank of CanadaReiterated RatingOutperformC$28.00
5/21/2021Royal Bank of CanadaReiterated RatingOutperformC$28.00
5/7/2021Bloom BurtonUpgradeAccumulate ➝ Buy
5/7/2021Royal Bank of CanadaLower TargetOutperformC$28.00
4/29/2021Royal Bank of CanadaReiterated RatingOutperformC$32.00
11/3/2020Bloom BurtonDowngradeBuy ➝ Accumulate
10/17/2019Cantor FitzgeraldReiterated RatingOverweight
10/2/2019Bloom BurtonReiterated RatingBuy
3/20/2019Cantor FitzgeraldReiterated RatingOverweight
3/19/2019SVB LeerinkReiterated RatingOutperform
(Data available from 11/28/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Read More

Today's Range

Now: C$16.76
Low: C$16.41
High: C$17.46

50 Day Range

MA: C$16.76
Low: C$16.76
High: C$16.76

52 Week Range

Now: C$16.76
Low: C$11.77
High: C$26.00

Volume

4,611,683 shs

Average Volume

229,895 shs

Market Capitalization

C$2.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aurinia Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Aurinia Pharmaceuticals in the last twelve months:
View the latest analyst ratings for AUP.

What is the current price target for Aurinia Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Aurinia Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Aurinia Pharmaceuticals in the next year.
View the latest price targets for AUP.

What is the current consensus analyst rating for Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AUP.

What other companies compete with Aurinia Pharmaceuticals?

How do I contact Aurinia Pharmaceuticals' investor relations team?

Aurinia Pharmaceuticals' physical mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company's listed phone number is +1-250-7084272. The official website for Aurinia Pharmaceuticals is www.auriniapharma.com. Learn More about contacing Aurinia Pharmaceuticals investor relations.